Načítá se...
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
BACKGROUND: The ‘Prediction Of Survival in Advanced Sorafenib‐treated HCC’ (PROSASH) model addressed the heterogeneous survival of patients with hepatocellular carcinoma (HCC) treated with sorafenib in clinical trials but requires validation in daily clinical practice. This study aimed to validate,...
Uloženo v:
| Vydáno v: | Liver Int |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6973249/ https://ncbi.nlm.nih.gov/pubmed/31579990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14270 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|